Search

Displaying results 1441 - 1450 of 7536 in total
  1. Drug

    Enoxaparin

    go.drugbank.com/drugs/DB01225
    ApprovedInvestigational

    Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. … [L31393] Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.

    Products: KLEXANE 10000 IE 100MG O S, KLEXANE 4000 IE 40MG O SI.
  2. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.

    Synonyms: (glycolato-O,O')diammineplatinum(II)
  3. Drug

    Colchicine

    go.drugbank.com/drugs/DB01394
    ApprovedInvestigational

    Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961.

    Categories: Preparations With No Effect on Uric Acid Metabolism
  4. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.

  5. Drug

    Calcium threonate

    go.drugbank.com/drugs/DB11168
    ApprovedWithdrawn

    Therapeutic efficacy of calcium threonate in reducing was studied and investigated due to the hypothesis that it may play a role in the mineralization process through its positive action on vitamin C. … L-threonate is an active metabolite of vitamin C that mediates a stimulatory action on vitamin C uptake [A27266].

    Mixtures: UltimateCare ONE NF
  6. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.

  7. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain … in studies as early as the 1950s) first-generation antihistamines were not optimally investigated [A32705].

  8. Drug

    Verteporfin

    go.drugbank.com/drugs/DB00460
    ApprovedInvestigational

    Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet … oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

  9. Drug

    Poloxamer 188

    go.drugbank.com/drugs/DB11333
    Approved

    P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217]. … Composed of two hydrophilic side-chains attached to a hydrophobic center core [A27218], its average molecular weight is 8400 Daltons.

  10. Drug

    Gonadorelin

    go.drugbank.com/drugs/DB00644
    ApprovedInvestigationalVet approved

    Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormon...